ReviewBreast cancer (Dove Medical Press)2015
Cardiac risk in the treatment of breast cancer: assessment and management.
Review in Breast cancer (Dove Medical Press), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of physical exercise programs in breast cancer survivors on health-related quality of life, physical fitness, and body composition: Evidence from systematic reviews and meta-analyses.Frontiers in oncology · 2022Pooled it
- Survival benefits of postoperative radiotherapy in patients with cTBMC women's health · 2024Article
- Outcomes of physical exercises on initiation, progression, and treatment of breast cancer.Cell communication and signaling : CCS · 2024Review
- Comparing the effects of various β-blockers on cardiovascular mortality in breast cancer patients.Cardio-oncology (London, England) · 2024Article
- Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients.BMC cancer · 2023Observational
- Euterpe oleracea extract (açaí) exhibits cardioprotective effects after chemotherapy treatment in a breast cancer model.BMC complementary medicine and therapies · 2023Article
- Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review.Journal of cardiovascular development and disease · 2022Review
- Review
- Clinical Effectiveness and Safety of Chinese Herbal Medicine Compound Kushen Injection as an Add-On Treatment for Breast Cancer: A Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Future Perspectives of Proton Therapy in Minimizing the Toxicity of Breast Cancer Radiotherapy.Journal of personalized medicine · 2021Review
- Right ventricular dysfunction in patients with diffuse large B-cell lymphoma undergoing anthracycline-based chemotherapy: a 2D strain and 3D echocardiography study.The international journal of cardiovascular imaging · 2021Article
- Cardiovascular Assessment Tool for Breast Cancer Survivors and Oncology Providers: Usability Study.JMIR cancer · 2021Article
- NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.Breast (Edinburgh, Scotland) · 2020Observational
- Effects of physical exercise on outcomes of cardiac (dys)function in women with breast cancer undergoing anthracycline or trastuzumab treatment: study protocol for a systematic review.Systematic reviews · 2019Article
- Therapy-induced cardiotoxicity in breast cancer patients: a well-known yet unresolved problem.Discoveries (Craiova, Romania) · 2019Review
- The therapy is making me sick: how online portal communications between breast cancer patients and physicians indicate medication discontinuation.Journal of the American Medical Informatics Association : JAMIA · 2018Article
- Breast cancer mortality and associated factors in São Paulo State, Brazil: an ecological analysis.BMJ open · 2017Article
- Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications.Menopause (New York, N.Y.) · 2017Article
- Cardiotoxicity Following Cancer Treatment.The Ulster medical journal · 2017Review
- Current views on anthracycline cardiotoxicity.Heart failure reviews · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the number of long-term breast cancer survivors has increased, the side effects of adjuvant cancer therapy, such as cardiac toxicity, remain clinically important. Although the cardiac toxicity due to anthracyclines, radiotherapy, or trastuzumab is well-documented, several issues need to be clarified and are the subjects of extensive ongoing clinical research. This review summarizes the incidence of cardiac toxicity due to breast cancer adjuvant therapy and highlights the current trends in early detection and management of cardiac toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.